APLLTD:NSE-Alembic Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 604.65

Change

+4.85 (+0.81)%

Market Cap

INR 121.30B

Volume

0.11M

Avg Analyst Target

INR 622.75 (+2.99%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

APLLTD Stock Forecast & Price:
Based on the Alembic Pharmaceuticals Limited stock forecasts from 4 analysts, the average analyst target price for Alembic Pharmaceuticals Limited is INR 622.75 over the next 12 months. Alembic Pharmaceuticals Limited’s average analyst rating is Sell. Stock Target Advisor’s own stock analysis of Alembic Pharmaceuticals Limited is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, Alembic Pharmaceuticals Limited’s stock price was INR 604.65. Alembic Pharmaceuticals Limited’s stock price has changed by -0.77% over the past week, -6.72% over the past month and -23.37% over the last year.

About Alembic Pharmaceuticals Limited (APLLTD:NSE)

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations. The company also provides branded and generic formulations in various therapeutic areas, such as ...Read More

Company Website : https://alembicpharmaceuticals.com

Address : Alembic Road, Vadodara, India, 390003

Employees : 12,216

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.72

52 Week High : 850.92

52 Week Low : 577.75

200 Day Moving Average : 723.75

50 Day Moving Average : 649.72

Shares Held By Insiders : 70.27%

Shares Held by Institutions : 15.01%

Dividend Yield : 1.68%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+17.95 (+1.93%)

 INR2,256.45B 58.05 28.62
DIVISLAB:NSE Divi's Laboratories Limited

+11.55 (+0.31%)

 INR982.22B 31.09 23.64
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-25.00 (-0.57%)

 INR718.64B 24.22 12.88
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+14.05 (+0.91%)

 INR525.13B 65.61 24.96
ZYDUSLIFE:NSE Zydus Lifesciences Limited

+4.05 (+1.06%)

 INR392.29B 18.28 10.34
ALKEM:NSE Alkem Laboratories Limited

+17.35 (+0.53%)

 INR390.28B 30.20 22.56
AUROPHARMA:NSE Aurobindo Pharma Limited

+0.90 (+0.18%)

 INR308.18B 12.48 6.68
LUPIN:NSE Lupin Limited

+25.05 (+3.83%)

 INR304.13B 25.10 -87.34
LAURUSLABS:NSE Laurus Labs Limited

+3.55 (+0.70%)

 INR274.16B 32.84 19.79
IPCALAB:NSE IPCA Laboratories Limited

+5.60 (+0.62%)

 INR225.42B 31.93 17.59

ETFs Containing APLLTD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.60% 40% F 22% F
Dividend Return 1.25% 80% B- 65% D
Total Return -23.35% 43% F 23% F
Trailing 12 Months  
Capital Gain -23.28% 48% F 20% F
Dividend Return 1.27% 79% C+ 62% D-
Total Return -22.01% 51% F 21% F
Trailing 5 Years  
Capital Gain 19.46% 38% F 51% F
Dividend Return 6.62% 83% B 70% C-
Total Return 26.08% 41% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 14.27% 36% F 45% F
Dividend Return 0.79% 78% C+ 56% F
Total Return 15.06% 35% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 37.64% 76% C 73% C
Risk Adjusted Return 40.01% 50% F 59% F
Market Capitalization 121.30B 83% B 84% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 41.77 21% F 25% F
Price/Book Ratio 2.24 59% F 48% F
Price / Cash Flow Ratio 21.96 49% F 30% F
EV/EBITDA 17.58 35% F 30% F
Management Effectiveness  
Return on Equity 10.11% 41% F 47% F
Return on Invested Capital 10.49% 58% F 62% D-
Return on Assets 5.31% 48% F 58% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield 1.68% 87% B+ 72% C-
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.72 53% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector